MarketBeat
22 Nov 2026, 14:12 UTC · 1h ago
Compass Pathways Sees Potential Fast FDA Review for Psilocybin Depression Treatment
Impact · against what's priced in
Compass Pathways is positioned for a potential H1 2027 commercial launch with a high-margin strategy leveraging existing SPRAVATO infrastructure. The combination of a rapid FDA review timeline and premium pricing expectations provides a positive catalyst for revenue projections.
- CMPS+0.70
No priced-in read yet





